Undisclosed pharma to deploy MDdatacor clinical trial screening and recruitment solution



FasTrac is designed to allow trial sponsors and clinical research organizations to accelerate Phase III and Phase IV trial recruitment by identifying patients within an investigator's clinical practice that meet the protocol's inclusion and exclusion criteria.

This contract further validates our belief that FasTrac offers trial sponsors and clinical research organizations many advantages over other patient recruitment and screening methods," said Blake Whitney,
MDdatacor Chairman, President and CEO. "Ultimately, FasTrac saves the trial sponsor both time and money by greatly compressing the clinical trial patient recruitment process."

According to MDdatacor, with FasTrac, a trial sponsor or clinical research organization provides MDdatacor with the trial protocol and the company then creates a database search using the protocol's inclusion and exclusion criteria which is in turn run against patient data from the sponsor's clinical sites. A list of patients who meet the trial criteria is presented back to authorized personnel at each site for follow-up by their research staff.

"We have an active research department and it can be difficult satisfying patient recruitment goals for our many ongoing clinical trials," said Paul Seigel, Managing Partner at the Miami Cardiology Group. "By utilizing FasTrac, my research staff can reduce our 10,000 active patient charts to the 30 or 40 patients who are eligible to participate in a particular study. This service saves us a tremendous amount of time and greatly increases my staff's productivity, enabling us to participate in more trials than we could previously. Our patients also appreciate being notified about ongoing studies, since it may provide them with early access to promising new medical therapies."